New Delhi, Sep 28 (PTI) Biocon on Saturday said the US health regulator has issued four observations after inspecting its Bengaluru-based API (active pharmaceutical ingredient) facility.

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.

Also Read | Noida Shocker: 62-Year-Old Man Kills Wife with Iron Rod, Faces Charges Under Section 105 of Bharatiya Nyaya Sanhita, Arrested.

"Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time," it added.

The company does not foresee any impact on the business, Biocon said.

Also Read | 7th Pay Commission: Tamil Nadu Govt Likely to Announce 4% DA Hike For Its Employees Ahead of Diwali, Says Report.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)